DYRK1B and cancer: Indeed, the usage of Dyrk1B inhibitor EHT5372 (Figure 3) enhanced the toxicity of mTOR inhibitor RAD001 in pancreatic Panc1 and ovarian TOV21G, SKOV3, and OVCAR3 cancer cells [44].